Intra-Cellular Therapies Inc to Discuss Positive Topline Results from Study 402 - Conference Call Transcript
Good morning, ladies and gentlemen, and welcome to the Intra-Cellular Therapies conference call announcing the top line results from Study 402. (Operator Instructions) As a reminder, today's conference call is being recorded. I would like to turn the conference over to your host, Dr. Juan Sanchez, Vice President, Corporate Communications and Investor Relations. Please go ahead.
Thank you, operator. Good morning and thank you for joining us on today's conference call announcing the positive top line results from Study 402, our study evaluating lumateperone as an adjunctive therapy in patients with bipolar depression.
Our press release announcing the results crossed the wire a short time ago and is available on our website. Joining me on the call today are Dr. Sharon Mates, Chairman and Chief Executive Officer; Dr. Andrew Satlin, Executive Vice President and Chief Medical Officer; Dr. Suresh Durgam, Senior Vice President of Late-Stage Clinical Development and
Access to All Earning Calls and Stock Analysis | |
30-Year Financial on one screen | |
All-in-one Stock Screener with unlimited filters | |
Customizable Stock Dashboard | |
Real Time Insider Trading Transactions | |
8,000+ Institutional investors’ 13F holdings | |
Powerful Excel Add-in and Google sheets Add-on | |
All data downloadable | |
Quick customer support | |
And much more... |